Clinical trials: Liver Metastases of Colorectal Cancer
Liver Metastases From Colorectal Cancer
The Role of the Imaging FAPI PET/CT in Exploring the Microenvironment of Colorectal Cancer Liver Metastases
FAPI PET/CT molecular imaging represents a cutting-edge advancement in oncological imaging, particularly for the preoperative assessment of colorectal liver metastases (CRLM).
- Trial name
- FOAM (NCT07109440)
- Testing
- FAPI PET/CT
- Where
- Belgium
- Volunteers
- 50 people
- Sponsor
- Jules Bordet Institute
Liver Metastases, Hepatocellular Carcinoma
Irreversible Electroporation of Unresectable Liver Tumors
The aim of this study is to evaluate the safety and feasibility of curative intended irreversible electroporation (IRE) in the treatment of liver tumors neighboring major vessels or bile ducts.
- Conditions
- Liver Metastases, Hepatocellular Carcinoma, Bile Duct Cancer
- Trial name
- NCT04404647
- Testing
- Irreversible electroporation
- Where
- Denmark
- Sponsor
- Ole Thorlacius-Ussing, MD, DMSc, Professor of Surgery
Colorectal Cancer, Immunotherapy
Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases
Colorectal cancer (CRC) is a significant cause of morbidity and mortality worldwide. Its early clinical manifestations are often subtle, leading to late-stage diagnosis in about 30% of cases with distant metastases.
- Conditions
- Colorectal Cancer, Immunotherapy, Radiotherapy, Targeted Therapy
- Trial name
- NCT06356584
- Testing
- Immunotherapy (Sintilimab), Targeted Therapy Agent (Fruquintinib), Radiotherapy (SBRT and LDRT)
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Shandong Cancer Hospital and Institute
Colon Cancer, Rectal Cancer
Selective Internal Radiation Therapy (SIRT) in Patients With Unresectable Colorectal Cancer Liver Metastases Who Failed Prior Intraarterial Pump Chemotherapy
This study is being done with a new therapy called "Selective Internal Radiation Therapy" (known as SIRT). Radiation is an effective treatment for destroying tumors. It is widely used in cancer treatment.
- Trial name
- NCT00972036
- Testing
- SIR-spheres® (Selective Internal Radiation Therapy)
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colon Cancer Liver Metastasis, Contrast Enhances Intraoperative Ultrasound
Detection Rate of Liver Metastases With Contrast Enhanced Intraoperative Ultrasound Compared to Regular Imaging
The study compares the established imaging techniques (CT, MRT, Contrast Ultrasound) with the new method of intraoperative contrast enhanced ultrasound to compare all methods for their rate of detection of colorectal liver…
- Conditions
- Colon Cancer Liver Metastasis, Contrast Enhances Intraoperative Ultrasound, Imaging for Liver Cancer, Imaging for Liver Metastasis
- Trial name
- CEIOUS-Liver (NCT01522209)
- Testing
- Liver Surgery, Contrast Enhanced Ultrasound, CT Scan (standard)
- Where
- Germany
- Volunteers
- 59 people
- Sponsor
- Asklepios Kliniken Hamburg GmbH
Colorectal Cancer, Metastatic to the Liver
Utility of Intra-operative Image Guidance System for Missing Metastases
Intraoperatively, the surgeon will interrogate the liver with ultrasound. The time spent by the surgeon using the ultrasound is recorded.
- Trial name
- NCT02806037
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Colorectal Cancer
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
The main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC).
- Trial name
- CANTOR (NCT06792695)
- Testing
- Volrustomig, FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan), Bevacizumab
- Where
- 56 sites in United States, Australia and 10 more
- Volunteers
- 82 people
- Sponsor
- AstraZeneca
Colorectal Cancer Metastatic to Liver
The QL1706 Combined With Chemotherapy and Either Cetuximab or Bevacizumab in Potentially Resectable Colorectal Cancer Patients With Liver Metastases
The goal of this clinical trial is to learn if QL1706 (Iparomlimab/ Tuvonralimab)+ chemotherapy+ cetuximab/bevacizumab works to treat potentially resectable colorectal cancer patients with liver metastases in adults.
- Trial name
- NCT07863869
- Testing
- Arm A, Arm B
- Volunteers
- 102 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Preventive Effect of Quintuple Therapy on Metachronous Liver Metastases in Patients With Colorectal Cancer
Early Blocking Strategy for Metachronous Liver Metastasis of Colorectal Cancer Based on Pre-hepatic CTC Detection
In this study, the Quintuple method was applied for early intervention of prehepatic CTC-positive bowel cancer patients without dominant liver metastasis, aiming to explore the blocking effect of the Quintuple method on the…
- Trial name
- NCT05720559
- Testing
- Oxaliplatin, S1, Cetuximab
- Volunteers
- 100 people
- Sponsor
- Liaoning Cancer Hospital & Institute
Acinar Cell Adenocarcinoma of the Pancreas, Adenocarcinoma of the Gallbladder
Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
This study is being done to determine the dose of a chemotherapy drug (irinotecan [irinotecan hydrochloride]) that can be tolerated as part of a combination of drugs.
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Adenocarcinoma of the Gallbladder, Adenocarcinoma of Unknown Primary, Adult Primary Cholangiocellular Carcinoma
- Trial name
- NCT01643499
- Testing
- oxaliplatin, irinotecan hydrochloride, leucovorin calcium
- Where
- 2 sites in United States
- Volunteers
- 79 people
- Sponsor
- University of Chicago
Colorectal Cancer
The Efficacy and Safety of Lcaritin Combined With Bevacizumab and FOLFIRI in Treatment of Liver Metastases From Colorectal Cancer
To evaluate the efficacy and safety of the combination regimen of Icaritin with bevacizumab + FOLFIRI in patients with liver metastases from advanced colorectal cancer.
- Trial name
- NCT06269445
- Testing
- Icaritin Combined With Bevacizumab and FOLFIRI
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sir Run Run Shaw Hospital
Colorectal Cancer
A Study of Bevacizumab Plus 5-Flurouracil (5-FU) Based Doublet Chemotherapy as Neoadjuvant Therapy for Participants With Previously Untreated Unresectable Liver-Only Metastases From Colorectal Cancer
This open-label, single arm, multicenter study evaluated the resection rate in participants with colorectal cancer and previously untreated unresectable liver-only metastases after adding bevacizumab to 5-FU based doublet…
- Trial name
- NCT01695772
- Testing
- 5-FU based doublet chemotherapy, bevacizumab
- Where
- 7 sites in China
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
Colorectal Neoplasms, Liver Metastases
Oxaliplatin and Capecitabine Versus Follow-up After Resection of Colorectal Liver Metastases
Primary endpoint of the study is to prove the superiority of an adjuvant therapy with oxaliplatin/ capecitabine until the first occurrence of appearance of a tumour.
- Trial name
- NCT00156975
- Testing
- Capecitabine, Oxaliplatin
- Where
- 3 sites in Germany
- Volunteers
- 384 people
- Sponsor
- Arbeitsgruppe Lebermetastasen und Tumoren
Colorectal Cancer, Colorectal Neoplasms Malignant
Simultaneous vs. Staged Resection of Colorectal Cancer With Synchronous Liver Metastases
The SYLMET Trial is a randomized trial to compare simultaneous and two-staged resection of primary colorectal and synchronous liver metastases.
- Conditions
- Colorectal Cancer, Colorectal Neoplasms Malignant, Liver Metastasis Colon Cancer, Liver Metastases
- Trial name
- SYLMET (NCT06200831)
- Testing
- Staged resection, Simultaneous resection
- Where
- Norway
- Volunteers
- 80 people
- Sponsor
- Oslo University Hospital
Colorectal Cancer, Liver Metastasis
Feasibility Study of Neoadjuvant Chemotherapy Modified FOLFOX6 for Resectable Liver Metastases of Colorectal Cancers
The purpose of this study is to evaluate the safety of liver resection for metastatic, resectable lesions from colorectal cancers after systemic chemotherapy.
- Trial name
- NCT00594529
- Testing
- Surgery
- Where
- Japan
- Volunteers
- 27 people
- Sponsor
- Kyoto University
Colorectal Cancer, Metastatic Cancer
Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more tumor cells.
- Trial name
- NCT00020501
- Testing
- FOLFIRI regimen, floxuridine, fluorouracil
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Colorectal Neoplasms, Neoplasm Metastasis
New Adjuvant Chemotherapy of Asymptomatic Resectable Primary Lesion With Unresectable Liver-limited Metastases
To evaluate the survival benefit of pre-operation chemotherapy of primary tumor tesection (PTR) compared upfront PTR for colorectal cancer (CRC) patients with an asymptomatic resectable primary tumor and synchronous unresectable…
- Conditions
- Colorectal Neoplasms, Neoplasm Metastasis, Liver Neoplasms, Chemotherapy; Maternal, Affecting Fetus
- Trial name
- NCT01307878
- Testing
- chemotherapy ± targeted therapy
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Fudan University
Liver Metastases, Colorectal Cancer Metastatic
Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis
The objective of this study is to evaluate the efficacy and safety of cryoablation combined with Sintilimab plus regorafenib for patients with colorectal cancer liver metastasis in the third-line setting.
- Trial name
- NCT05057052
- Testing
- Sintilimab, Regorafenib, US/CT-guided Percutaneous Cryoablation
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fudan University
Colorectal Cancer
Resorbable Barrier for the Prevention of Abdominal and Peri-hepatic Adhesion Formation
The purpose of this study is to evaluate the efficiency of a resorbable barrier membrane for the prevention of abdominal and peri-hepatic adhesion in patients with colorectal cancer requiring two-stage surgery for the resection…
- Trial name
- SEPRAC2T (NCT01262417)
- Testing
- - use of resorbable membrane Seprafilm, without resorbable barrier (seprafilm)
- Where
- 17 sites in France
- Volunteers
- 60 people
- Sponsor
- Centre Leon Berard
Liver Metastasis Colon Cancer
Irreversible Electroporation (NanoKnife ®) and Immunotherapy for the Treatment of Stage IV Colorectal Cancer
The goal of this pilot clinical trial is to learn about the combination of immune boosting drugs and irreversible electroporation (IRE) in patients with colon cancer that has spread to the liver (metastasis).
- Trial name
- NCT06047015
- Testing
- IRE plus checkpoint inhibitor, IRE plus Checkpoint Inhibitor plus CpG-ODN
- Volunteers
- 12 people
- Sponsor
- University of Saskatchewan